Manufacturing, latest filing in October 2026

Accelevation Holdings Corp. IPO

Accelevation Holdings Corp. filed a Form S-1 registration statement for an initial public offering on 2026-09-02. It has amended it 2 times. It filed its final prospectus on 2026-10-01, at a public offering price of $18.00 per share. Each fact below is quoted from the filing named with it.

Swipe the table sideways to see every column.

We have been approved to list our Class A common stock on The Nasdaq Global Select Market, or Nasdaq, under the symbol “ACCV.”From the 424B4 filed 2026-10-01

See “Use of Proceeds.” Prior to this offering, there was no public market for the Class A common stock of Accelevation Holdings Corp. The initial public offering price per share of the Class A common stock is $18.00 .From the 424B4 filed 2026-10-01

We intend to use the net proceeds from this offering to repay approximately $170.6 million of outstanding borrowings under our Credit Agreement.From the 424B4 filed 2026-10-01

Swipe the table sideways to see every column.

Actuate Therapeutics, Inc. IPO

Actuate Therapeutics, Inc. filed a Form S-1 registration statement for an initial public offering on 2025-03-28. It has amended it 5 times. It filed its final prospectus on 2024-08-13, at a public offering price of $8.00 per share. Each fact below is quoted from the filing named with it.

Swipe the table sideways to see every column.

Our common stock is listed on the Nasdaq Global Market under the symbol “ACTU.” On October 15, 2026, the last reported sales price of our common stock on the Nasdaq Global Market was $0.50 per share.From the S-1/A filed 2026-10-19

We are selling 40,000,000 shares of our common stock and 20,000,000 warrants (each a “purchase warrant”) to purchase 20,000,000 shares of our common stock.From the S-1/A filed 2026-10-19

The initial public offering price per share of common stock is $8.00.From the 424B4 filed 2024-08-13

We expect to use the net proceeds from this offering for working capital and general corporate purposes.From the S-1/A filed 2026-10-19

Swipe the table sideways to see every column.

Alopexx, Inc. IPO

Alopexx, Inc. has a Form S-1 registration statement on file for an initial public offering; the original was filed before the period this page covers, and the earliest filing here is an amendment filed on 2024-09-09. Amendments on record here: 7. As of its latest filing, on 2026-10-27, it has not priced the offering or withdrawn it. Each fact below is quoted from the filing named with it.

We have applied to have our common stock listed on the NYSE American LLC (the “NYSE American”) under the symbol “ALPX”.From the S-1/A filed 2026-10-27

We estimate that the initial public offering price of our shares will be between $10.00 and $12.00 per share.From the S-1/A filed 2026-10-27

We currently intend to use the net proceeds from this offering to advance our product candidates, fund completion of proof -of-concept clinical trials of vaccine AV0328 and monoclonal antibody F598 manufacturing scale -up activities, and for general corporate purposes, including working capital, operating expenses and capital expenditures.From the S-1/A filed 2026-10-27

Our net losses were $2,608,394 and $3,060,624 for the years ended December 31, 2025 and 2024, respectively.From the S-1/A filed 2026-10-27

Swipe the table sideways to see every column.

Amaero Inc. IPO

Amaero Inc. filed a Form S-1 registration statement for an initial public offering on 2026-08-28. It has amended it 3 times. It filed its final prospectus on 2026-10-15, at a public offering price of $4.25 per share. Each fact below is quoted from the filing named with it.

The initial public offering price is $4.25 per share of our common stock.We have been approved to list our common stock on the Nasdaq Capital Market (the “Nasdaq”) under the symbol “AMRO.”From the 424B4 filed 2026-10-15

This is an initial public offering of shares of common stock of Amaero Inc. We are selling 4,705,883 shares of our common stock.From the 424B4 filed 2026-10-15

The initial public offering price is $4.25 per share of our common stock.We have been approved to list our common stock on the Nasdaq Capital Market (the “Nasdaq”) under the symbol “AMRO.”From the 424B4 filed 2026-10-15

In connection with our expansion efforts, we have realized net losses from continuing operations of $13.4 million for the six months ended June 30, 2026, and $18.5 million and $13.4 million for the years ended December 31, 2025 and 2024, respectively.From the S-1/A filed 2026-10-08

Swipe the table sideways to see every column.

Arxis, Inc. IPO

Arxis, Inc. filed a Form S-1 registration statement for an initial public offering on 2026-03-24. It has amended it 2 times. It filed its final prospectus on 2026-04-16, at a public offering price of $28.00 per share. Each fact below is quoted from the filing named with it.

Swipe the table sideways to see every column.

Our Class A common stock has been approved for listing on the Nasdaq Global Select Market (“Nasdaq”) under the symbol “ARXS.”From the 424B4 filed 2026-04-16

This is an initial public offering of shares of Class A common stock by Arxis, Inc. We are offering 40,500,000 shares of Class A common stock.From the 424B4 filed 2026-04-16

The initial public offering price is $28.00 per share.From the 424B4 filed 2026-04-16

We generated revenue of $1,591.0 million for the year ended December 31, 2025, which represents a 10.5% revenue compound annual growth rate (“CAGR”) from the year ended December 31, 2021, calculated based on pro forma revenue from 2021 to 2025, while generating net income of $46.0 million for the year ended December 31, 2025, and a net loss of $55.5 million and $59.9 million for the years ended December 31, 2024 and 2023, respectively.From the S-1/A filed 2026-04-10

Arxis is a leading designer and manufacturer of proprietary, mission-critical electronic and mechanical components engineered for cutting edge performance in extreme environments.~$1.6Bn 2025 Revenue~$46MM 2025 Net Income~$571MM 2025 Adj.From the S-1/A filed 2026-04-10

Swipe the table sideways to see every column.

Bioventrix, Inc. IPO

Bioventrix, Inc. filed a Form S-1 registration statement for an initial public offering on 2026-02-12. It has amended it 3 times. It asked for the registration statement to be withdrawn on 2026-10-14. Each fact below is quoted from the filing named with it.

Swipe the table sideways to see every column.

We have applied to have our common stock listed on the Nasdaq Capital Market (“Nasdaq”) under the symbol “BVXX.” No assurance can be given that our application will be approved by Nasdaq.From the S-1/A filed 2026-05-29

We have reported net losses of approximately $1.2 million and $3.3 million for the three months ended March 31, 2025 and 2026, respectively.From the S-1/A filed 2026-05-29

Pursuant to Rule 477 promulgated under the Securities Act of 1933, as amended (the “Securities Act”), BioVentrix, Inc. (the “Company”) hereby respectfully requests that the Securities and Exchange Commission (the “Commission”) consent to the withdrawal of the Company’s Registration Statement on Form S-1 (File No. 333-293418), together with the exhibits thereto, which was filed initially filed with the Commission on February 12, 2026 (the “Registration Statement”), as of the date hereof or at the earliest practicable date hereafter.From the RW filed 2026-10-14

Swipe the table sideways to see every column.

BirchBioMed Inc. IPO

BirchBioMed Inc. filed a Form S-1 registration statement for an initial public offering on 2026-08-12. It has amended it 1 time. As of its latest filing, on 2026-10-09, it has not priced the offering or withdrawn it. Each fact below is quoted from the filing named with it.

Swipe the table sideways to see every column.

We have applied to list our common shares on the Nasdaq under the symbol “BRBM . ” We expect our common shares to begin trading on Nasdaq on or about , 2026.From the S-1/A filed 2026-10-09

According to Brand Essence Market Research, the global liver cirrhosis treatment market in terms of revenue was worth $4.27 billion in 2020 and is expected to reach $8.17 billion in 2027, growing at a CAGR of 9.97% from 2021 to 2027.From the S-1 filed 2026-08-12

We have recurring net losses, which have resulted in an accumulated deficit of $25,864,829 as of June 30, 2026.From the S-1/A filed 2026-10-09

Swipe the table sideways to see every column.

Green Circle Decarbonize Technology Ltd IPO

Green Circle Decarbonize Technology Ltd filed a Form F-1 registration statement for an initial public offering on 2026-09-21. It has amended it 9 times. It filed its final prospectus on 2026-01-13. Each fact below is quoted from the filing named with it.

Swipe the table sideways to see every column.

Our Class A Ordinary Shares are listed on the NYSE American under the ticker symbol “GCDT”.From the F-1 filed 2026-10-14

We intend to use the net proceeds from sales of Class A Ordinary Shares under the Equity Purchase Agreement for working capital and general corporate purposes.From the F-1 filed 2026-10-14

We generated revenue of approximately HK$16.6 million and approximately HK$5.2 million for the years ended March 31, 2025 and 2024, respectively.From the F-1/A filed 2025-11-28

Swipe the table sideways to see every column.

Kepuni Holdings Inc. IPO

Kepuni Holdings Inc. has a Form F-1 registration statement on file for an initial public offering; the original was filed before the period this page covers, and the earliest filing here is an amendment filed on 2024-09-30. Amendments on record here: 6. It asked for the registration statement to be withdrawn on 2026-10-19. Each fact below is quoted from the filing named with it.

We plan to list our ordinary shares on the Nasdaq Capital Market, or Nasdaq, under the symbol “KPN”.From the F-1/A filed 2026-03-12

This is the initial public offering of 2,500,000 ordinary shares, par value $0.0001 per share, of Kepuni Holdings Inc. (“we,” “us,” “our company,” the “Company,” “our,” or “Kepuni Holdings”).From the F-1/A filed 2026-03-12

We expect the initial public offering price will be between $5.00 and $7.00 per ordinary share.From the F-1/A filed 2026-03-12

As of December 31, 2024, we had a working capital deficit of US$4,122,759, incurred a net loss of US$1,410,990, and experienced operating cash outflows of US$ 813,091 for the year ended December 31, 2024.From the F-1/A filed 2026-03-12

Pursuant to Rule 477 under the Securities Act of 1933 (the “Act”), Kepuni Holdings Inc. (the “Company”) respectfully requests the immediate withdrawal of its Registration Statement on Form F-1 (File No. 333-259193) initially filed with the United States Securities and Exchange Commission (the “Commission”) on August 31, 2021, together with all exhibits, amendments and post-effective amendments thereto (the “Registration Statement”), with such application to be approved effective as of the date hereof or at the earliest practicable date thereafter.From the RW filed 2026-10-19

Swipe the table sideways to see every column.

Neo Aeronautics, Inc. IPO

Neo Aeronautics, Inc. filed a Form S-1 registration statement for an initial public offering on 2025-12-19. It has amended it 2 times. As of its latest filing, on 2026-10-22, it has not priced the offering or withdrawn it. Each fact below is quoted from the filing named with it.

We have applied to list our Class A Common Stock on the NYSE American LLC (“NYSE American”) under the symbol “NEOA.” At this time, NYSE American has not yet approved our application to list our Class A Common Stock.From the S-1/A filed 2026-10-22

We are offering 3,750,000 shares of Class A Common Stock, and the Selling Stockholders (as defined and named herein) are offering an aggregate of 1,250,000 shares of Class A Common Stock to be sold in the offering pursuant to this prospectus.From the S-1/A filed 2026-10-22

We plan to use the net proceeds of this offering as follows:From the S-1/A filed 2026-10-22

For the six months ended June 30, 2026, the Company reported net losses of S$408,916 (US$315,984) and negative operating cash flows of S$470,135 (US$363,290).From the S-1/A filed 2026-10-22

Swipe the table sideways to see every column.

Retension Pharmaceuticals, Inc. IPO

Retension Pharmaceuticals, Inc. filed a Form S-1 registration statement for an initial public offering on 2026-09-18. It has amended it 2 times. It filed its final prospectus on 2026-10-09, at a public offering price of $12.00 per share. Each fact below is quoted from the filing named with it.

Swipe the table sideways to see every column.

Our common stock is listed on the Nasdaq Capital Market (“Nasdaq”), under the symbol “RTSN.”From the 424B4 filed 2026-10-09

This is the initial public offering of shares of common stock of Retension Pharmaceuticals, Inc. We are offering 3,750,000 shares of common stock in this offering.From the 424B4 filed 2026-10-09

an initial public offering price of $ 12.00 per share; andFrom the 424B4 filed 2026-10-09

We intend to use the net proceeds of this offering, together with our existing cash and cash equivalents to complete the Phase 2b clinical trial and prepare for, support and advance the planned Phase 3 clinical trial of RTN -001 in uHTN and the remainder for general corporate purposes and other operating expenses.From the 424B4 filed 2026-10-09

Our net losses were $6.3 million and $1.9 million for the fiscal years ended December 31, 2025 and 2024, respectively.From the S-1/A filed 2026-10-05

Swipe the table sideways to see every column.

Rothe Development, Inc. IPO

Rothe Development, Inc. filed a Form S-1 registration statement for an initial public offering on 2026-09-04. It has amended it 2 times. As of its latest filing, on 2026-10-05, it has not priced the offering or withdrawn it. Each fact below is quoted from the filing named with it.

Swipe the table sideways to see every column.

We have applied to list our Class B common stock on the Nasdaq Capital Market (“Nasdaq”) under the symbol “RDEV.” No assurance can be given that our listing application will be approved or that we will meet the initial listing requirements of Nasdaq.From the S-1/A filed 2026-10-05

For the year ended December 31, 2025, we generated revenue of $126.4 million but incurred a loss from operations of $0.7 million, compared to income from operations of $1.8 million for the year ended December 31, 2024.From the S-1/A filed 2026-10-05

Our gross margin decreased to 5.3% for fiscal year 2025 from 6.3% for fiscal year 2024 and our net income for fiscal year 2025 was $410,024, compared to $802,420 for fiscal year 2024.From the S-1/A filed 2026-10-05

Swipe the table sideways to see every column.

Starton Holdings, Inc. IPO

Starton Holdings, Inc. filed a Form S-1 registration statement for an initial public offering on 2025-12-11. It has amended it 6 times. As of its latest filing, on 2026-10-28, it has not priced the offering or withdrawn it. Each fact below is quoted from the filing named with it.

We have applied to list our shares of common stock on the Nasdaq Capital Market (“Nasdaq”) under the symbol “STA.” It is a condition to the closing of this offering that the common stock offered hereby has been duly listed on Nasdaq.From the S-1/A filed 2026-10-28

We currently intend to use the net proceeds from this offering to support our product development activities for our lead programs, STAR -LLD , including conducting clinical development and managing regulatory affairs for our product candidates; and for working capital and other general corporate purposes, including payment of certain outstanding trade payables and other amounts due and owing to related parties.From the S-1/A filed 2026-10-28

We incurred a net loss of $15.4 million for the year ended March 31, 2026, and a net loss of $3.4 million for the three months ended June 30, 2026.From the S-1/A filed 2026-10-28

Swipe the table sideways to see every column.